Objectives: This study compared the activity of telavancin, a novel multivalent lipoglycopeptide with rapid bactericidal activity, with those of five standard antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) against isolates of community-associated MRSA (CA-MRSA).
Introduction
Reports of methicillin-resistant Staphylococcus aureus (MRSA) originating in the community among people without traditional MRSA risk factors are increasing across geographically diverse regions. 1, 2 First described in the 1980s, MRSA infections acquired in the community traditionally have been associated with recent hospitalization or other contact with a healthcare facility, prolonged or recent antibiotic therapy, or injection drug use. 3 Community-acquired MRSA (CA-MRSA) infections have also appeared with greater frequency among athletic teams and in prison populations or in lower socioeconomic strata. However, not only has the incidence of CA-MRSA increased in several communities among those lacking established risk factors for infection, but strains of CA-MRSA recently have emerged as a cause of infections in healthcare facilities. 2, 4 The increasing incidence and emergence of CA-MRSA in healthcare settings combined with the inadvisability of relying solely on b-lactam antibiotics as empirical therapy for severe infections that may be staphylococcal in origin, underscore the need to pursue novel strategies for effectively treating CA-MRSA infections. Telavancin is a novel lipoglycopeptide with rapid bactericidal activity and multiple mechanisms of action against MRSA and other Gram-positive bacteria. 5, 6 To investigate the therapeutic potential of telavancin in CA-MRSA and further our understanding of the epidemiology of CA-MRSA infections, we performed an in vitro study on 60 CA-MRSA isolates obtained from our institution, comparing the activity of telavancin with that of five standard antibiotics. We assessed the comparative in vitro activity of telavancin against both Panton-Valentine leucocidin (PVL)-and non-PVL-producing strains of CA-MRSA. 
Materials and methods

CA-MRSA isolates
Sixty strains of MRSA, meeting the CDC definition of CA-MRSA previously described, 1 were isolated from 60 patients admitted to St John Hospital and Medical Center, Detroit, MI, USA, from 1 July 2003 to 1 December 2005 who were found to have a culture positive for MRSA within 48 h of admission, as recorded in the microbiology laboratory database. MRSA isolates were identified using the Vitek 2 system (bioMérieux, Durham, NC, USA). There were no duplicate isolates from patients.
For an infection to be defined as an MRSA infection in this study, the following criteria had to be met by careful chart review: clinical evidence of infection, identification of MRSA from a sterile body site or from drainage obtained at a non-sterile site having evidence of infection and no identification of other pathogens involved. Cultures were performed on samples collected from blood (n ¼ 26), wound or tissue (n ¼ 31), sputum (n ¼ 1), catheter tip (n ¼ 1), or percutaneous endoscopic gastrostomy site (n ¼ 1). To avoid including nosocomial strains of MRSA, we excluded isolates from patients with cultures positive for MRSA after 48 h of hospitalization.
Molecular typing
PFGE was performed on all isolates, using the SmaI restriction endonuclease, and the findings were interpreted according to standard guidelines. 1, 4 Specimens from three predominant pulsed-field types, designated A, C and D, were typed by multilocus sequence typing.
1 Staphylococcal cassette chromosome (SCC) mec types were determined by a multiplex PCR method. 1, 4 The results were verified by PCR amplification of the cassette chromosome recombinase (ccr) gene and mec class type. 1 The PVL genes lukS-PV and lukF-PV were identified by PCR. 1 
Antimicrobials and in vitro susceptibility testing
The following antimicrobials were obtained in powder form and used in the in vitro experiments: telavancin (Theravance, Inc., South San Francisco, CA, USA), quinupristin/dalfopristin (King Pharmaceuticals, Inc., Cary, NC, USA), vancomycin (Eli Lilly and Company, Indianapolis, IN, USA), trimethoprim/sulfamethoxazole (Sigma-Aldrich Corporation, St Louis, MO, USA), linezolid (Pharmacia Corporation, Kalamazoo, MI, USA) and daptomycin (Cubist Pharmaceuticals, Lexington, MA, USA).
Microdilution tests using cation-adjusted Mueller -Hinton broth were used to determine the MICs of telavancin, quinupristin/dalfopristin, vancomycin, trimethoprim/sulfamethoxazole and linezolid for all isolates. For the determination of the MIC of daptomycin, additional calcium was added to bring the concentration of calcium to 50 mg/L. MIC values were determined in accordance with CLSI (formerly NCCLS) guidelines. 7 In keeping with these guidelines MIC values were read visually as the lowest drug concentration well with no visible bacterial growth. The MBC values of telavancin for all isolates were also determined according to CLSI guidelines.
Results
Molecular analyses
Molecular analyses indicated that 32 of the 60 isolates tested had the same profile as USA300, a MRSA clone identified as the predominant cause of CA-MRSA infections in the United States, and that they carried the SCCmec type IV allele, considered a marker for CA-MRSA, 2, 4 and harboured PVL genes (Table 1) .
PFGE profiles of representative isolates were generated from strains that were isolated on more than one occasion. The PFGE pattern from isolate A was indistinguishable from that of USA300. Additionally, MRSA clone USA100 and the sample PFGE strain E possessed identical PFGE profiles. A dendrogram analysis of the representative pulsed-field types was performed and showed the degree of relatedness; the most common isolate, designated A, was found in 32 patients and was identical to USA300, and the second most common isolate, E, was found in 6 patients and was identical to USA100. Based on the dendrogram, the remaining isolates were unrelated. Multilocus sequencing results were: strain A (3-3-1-1-4-4-3) , strain C (10-2-23-6-10-3-2), strain D (1-4-1-4-12-1-1) .
In vitro experiments
Telavancin was highly active against all 60 CA-MRSA isolates ( Table 2 ). The MIC and MBC ranges of telavancin both equalled 0.25 -1 mg/L, and the MIC 90 and MBC 90 values of telavancin were 0.5 and 1 mg/L, respectively. Telavancin was found to be bactericidal in this study, as its MBC was no more than 2-fold higher than its MIC for all CA-MRSA isolates tested except one. For example, the telavancin MBC/MIC ratios were 4 for all 60 isolates tested, 1 for 34 strains (57%) and 2 for 25 strains (42%). A single isolate yielded an MBC/MIC ratio of 4. Similar in vitro activity for telavancin and comparator agents was observed among CA-MRSA isolates having the same profile as USA300 (n ¼ 32) and among non-PVL-producing CA-MRSA isolates (n ¼ 28). Only one strain demonstrated resistance to trimethoprim/sulfamethoxazole; the MIC and MBC of telavancin for this strain were 0.5 and 1 mg/L, respectively.
Although CLSI breakpoints are not available at this time, telavancin achieves serum concentration levels that would inhibit all isolates after usual dosage. 
Discussion
Telavancin demonstrated bactericidal activity against all 60 CA-MRSA isolates in this study, including 32 possessing the SCCmec type IV allele, PVL genes and the same profile as USA300. Among isolates studied telavancin showed in vitro activity as good as comparator agents and thus offers notable therapeutic potential for CA-MRSA. In addition, other investigators have already demonstrated the excellent activity of telavancin against glycopeptide-intermediate staphylococcal species and vancomycin-resistant S. aureus. 8 Telavancin has demonstrated efficacy similar to that of standard therapy in Phase 2 trials for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. 9 Recently, the pooled results of two multinational, randomized, double-blinded Phase 3 trials in 1867 patients further demonstrated the efficacy of telavancin in complicated skin and skin structure infections caused by suspected or confirmed Gram-positive pathogens. 10 For the treatment of such infections, telavancin in both studies was found to be comparable to the mainstay MRSA antibiotic vancomycin. Telavancin achieved the primary end point of non-inferiority to vancomycin in clinical cure rate in clinically evaluable patients. In patients infected with MRSA in all study populations, however, the clinical, microbiological and overall therapeutic response rates consistently favoured telavancin.
With CA-MRSA infections in healthcare settings on the rise 2 and severe infections caused by CA-MRSA becoming less rare, a novel antimicrobial such as telavancin, which has demonstrated activity against both PVL-and non-PVL-producing strains of CA-MRSA in our study, may be an effective alternative in the treatment of CA-MRSA in nosocomial and community populations alike. 
